Published in Vaccine Weekly, January 8th, 2003
"The systemic administration of IL-2 can act as a potent adjuvant for T-cell-directed vaccine strategies. However, not only is the administration of IL-2 potentially toxic, but recent evidence suggests that it may also paradoxically limit the duration and magnitude of the cytotoxic T-cell response. A recently identified cytokine, IL-15, shares many properties with IL-2 and may provide a preferential means of augmenting T-cell-directed vaccine responses," stated M.P. Rubinstein and colleagues, Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly